Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 10:32 AM
Ignite Modification Date:
2025-12-26 @ 10:32 AM
NCT ID:
NCT04150328
Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed diagnosis of DLBCL
* Relapsed/refractory to at least one previous systemic therapy for DLBCL
* Received at least one, but no more than three previous systemic regimens for the treatment of DLBCL, including at least one anti-CD20 containing therapy
* Received lenalidomide monotherapy for R/R DLBCL while being considered not eligible for an ASCT
Exclusion Criteria:
* CNS involvement by lymphoma
* Patients who received lenalidomide in combination with another anti-lymphoma therapy (including radiation)
* Previously treated with anti-CD19-targeted therapy or immunomodulatory drugs
* Patients who previously underwent allogeneic SCT
* Known simultaneous detection of MYC and BCL2 or BCL6 translocation according to FISH
* Patients with a history of other malignancies within 5 years prior to lenalidomide treatment start
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04150328
Study Brief:
Protocol Section:
NCT04150328